148 results about "Bilirubin" patented technology

The invention provides an adsorbent capable of simultaneously adsorbing bilirubin and cytokines and a preparation method and application thereof, and the preparation method comprises the following steps: carrying out suspension polymerization reaction on a styrene monomer and a polyvinyl cross-linking agent in a dispersion medium under the action of a continuous multi-component pore-foaming agent and an initiator to prepare polystyrene-based macroporous resin; carrying out chloromethylation reaction on the polystyrene-based macroporous resin to prepare chlorine balls; carrying out post-crosslinking reaction on the chloromethylated beads to prepare the adsorbent capable of adsorbing bilirubin and cytokines at the same time; the continuous multi-component pore-foaming agent comprises a first pore-foaming agent, a second pore-foaming agent and a third pore-foaming agent of which the solubility parameters are gradually increased in sequence; the temperature of the suspension polymerization reaction is adjusted according to the mass fraction of the polyvinyl cross-linking agent in the monomer mixture and the solubility parameter of the continuous multi-component pore-foaming agent, and the monomer mixture is composed of styrene monomers and the polyvinyl cross-linking agent. The bilirubin and cell factors can be adsorbed at the same time, and the safety of blood purification is improved.

Wearable devices for measuring health indicators such as bilirubin are provided. The device includes a skin-facing side including a circuit board. The circuit board includes a spectrometer integrated circuit, at least one light emitting diode (LED) configured to direct light at the subject's skin where the LED is operably connected to a power source, at least one photodetector configured to receive light reflected from the subject's skin, and a microcontroller configured to perform spectral subtraction of said reflected light.

The invention discloses a heme oxygenase mutant and application of the heme oxygenase mutant in preparation of bilirubin through multienzyme coupling, and belongs to the field of biological catalysis engineering. The forward mutant of the heme oxygenase is obtained through a directed evolution technology, and heme can be efficiently catalyzed to synthesize biliverdin; the bilirubin is synthesized by further introducing biliverdin reductase, coupling cytochrome P450 reductase and formate dehydrogenase, and coupling the two core enzymes with foreign assistant enzymes to construct recombinant escherichia coli to catalyze heme to synthesize bilirubin. In the system, NADPH does not need to be exogenously added, the reaction time is about 4 h, the yield of bilirubin reaches 2.10 g / L, accumulation of intermediate products is not observed in the catalysis process, and the highest yield and the shortest reaction time in bilirubin synthesis reported at home and abroad at present are achieved. Compared with the traditional pig bile extraction, the method disclosed by the invention breaks through the resource limitation, is simple to operate and high in yield, and realizes efficient and green synthesis of bilirubin.

The invention provides a combined use of a hyaluronic acid-bilirubin conjugate and honokiol in preparation of a medicine for treating osteoarthritis. The invention provides a honokiol-loaded nanoparticle, which is characterized in that a hyaluronic acid-bilirubin conjugate and honokiol are used as raw materials to prepare a nanoparticle HKL-PNPs, and then the nanoparticle HKL-PNPs is modified by a mitochondrial targeting peptide to obtain the honokiol-loaded nanoparticle HKL-MPNPs. The invention also provides a bionic nanoparticle for treating bone joints. The bionic nanoparticle is prepared by wrapping the honokiol-loaded nanoparticle with an engineered cartilage cell membrane (ECM). According to the invention, cartilage cells with high expression of IL-1R2 are obtained through a gene editing method for the first time, and mitochondrial targeted nanoparticle cores loaded with Sirtuin-3 agonists are coated by cell membranes of the cells, so that the bionic nano preparation is obtained and is used for treating OA. The prepared bionic nano preparation not only can neutralize IL-1beta mediated inflammatory reaction, but also can recover Sirtuin-3 mediated mitochondrial function imbalance, so that the result of synergistic treatment of OA is achieved.

The invention belongs to the technical field of medical apparatus and instruments, and discloses a mechanical intelligence-based incubator closed blue light irradiation data management system, which comprises a state cluster data module for collecting multi-source heterogeneous data, correcting clock skew between an incubator and a preset biosensor through a space-time alignment protocol, and sending the corrected clock skew to a server; dynamically adjusting the sampling rate of the multi-source heterogeneous data based on the infant physiological data in the multi-source heterogeneous data after time alignment, and outputting a state cluster data packet with a timestamp; the layered extraction module is used for constructing a three-level feature processing assembly line based on the state cluster data packet, and comprises a base layer for calculating a base statistical magnitude through a sliding window; the logic layer generates a temperature and light effect index and a sealing safety coefficient according to the basic statistics and in combination with the multi-source heterogeneous data; the decision-making layer establishes a treatment efficiency prediction matrix based on a temperature-light effect index and a sealing safety coefficient, and predicts a correlation trend of blue light irradiation and bilirubin metabolism; the safety and the curative effect stability of infant treatment are improved.

The invention provides a bilirubin adsorbing material as well as a preparation method and application thereof, and belongs to the technical field of blood perfusion materials. The bilirubin adsorption material is mainly prepared from chitosan quaternary ammonium salt, microfibrillated cellulose, a surfactant and a cross-linking agent, wherein the surfactant is one or more of lauryl methacrylate, Span 80 and Span 85. The structure of the bilirubin adsorption material is that a hydrophilic polysaccharide chain is stabilized in a pore wall shell, and a hydrophobic chain of a surfactant is repelled and assembled to a pore wall core. When the bilirubin adsorption material adsorbs albumin-bilirubin, the adsorption effect is better than that of MFC / QCS frozen gel, and the adsorption capacity and the adsorption rate are enhanced along with the increase of the concentration of albumin.

The invention relates to the technical field of blood purification materials, in particular to a zirconium-titanium bimetal MOF hollow microsphere adsorbent and a preparation method and application thereof. The adsorbent is based on a Zr / Ti bimetallic node and a phosphonic acid-carboxylic acid mixed ligand, a composite MOF hollow microsphere structure with high stability and high specific surface area is constructed through a solvothermal and polymerization synergistic reaction in a water-in-oil suspension system, a phosphonic acid group and Zr are strongly coordinated to improve the stability of a framework, and the composite MOF hollow microsphere structure has a high specific surface area. The carboxylic acid group keeps the hydrophilicity of the pore channel; meanwhile, a cross-linked network of acrylamide and N, N '-methylene bisacrylamide penetrates through crystal gaps in the balling process, so that the material has excellent mechanical strength and fluid stability; and a sulphobetaine amphoteric polymer brush layer is constructed on the surface of the MOF through endogenous initiation point modification and surface in-situ controllable free radical polymerization technologies, so that protein adsorption and platelet adhesion are effectively inhibited, the blood compatibility is remarkably improved, and meanwhile, the channel accessibility is maintained to promote rapid diffusion and adsorption of bilirubin.

The utility model discloses a bilirubin adsorption column saturation detector, which relates to the technical field of bilirubin adsorption treatment and comprises a light-emitting device and a detection device, the light-emitting device is provided with a first light-emitting end and a second light-emitting end, and the detection device is provided with a first detection end and a second detection end. The first light-emitting end is constructed to enable light to penetrate through a plasma input tube of the bilirubin adsorption column and irradiate the first detection end, the first detection end is used for detecting the illumination intensity of the light penetrating through the plasma input tube, and the second light-emitting end is constructed to enable light to penetrate through a plasma output tube of the bilirubin adsorption column and irradiate the second detection end; the second detection end is used for detecting the illumination intensity of the light passing through the plasma output tube. The detector can more accurately detect the saturation of the adsorption column in real time in the adsorption treatment process of the adsorption column.

The invention relates to the technical field of biomedical detection, and discloses a portable urine component detection system and method based on a fluorescence sensor array. The system comprises a fluorescence sensor array, different fluorescence probes are used for detecting different trace components in urine, and fluorescence color gradient changes are generated through a probe-target object reaction, so that bilirubin, glucose and albumin in the urine are detected. The detection system comprises a micro-fluidic chip which integrates a capillary driving channel and a colorimetric reaction area and is used for sample transmission and reaction area positioning; an ultraviolet excitation light source and a multi-angle optical sensor are arranged in the camera obscura type color acquisition module, and the camera obscura type color acquisition module eliminates ambient light interference and captures fluorescence chromaticity signals; and the intelligent data processing system is integrated with an intelligent analysis end of the smart phone, establishes a quantitative relationship between chromaticity parameters (RGB and hue saturation) and the concentration of a target object through a machine learning model, and outputs a detection result in combination with an ambient light correction algorithm.

An eyeshade structure for bilirubin detection includes a body, a first detection module, and a second detection module. The body includes a bottom plate and a side wall. The side wall is connected to the bottom plate and forms an accommodating space with the bottom plate. The first detection module is arranged on the bottom plate. The second detection module is arranged on the bottom plate and is adjacent to the first detection module. The first detection module and the second detection module each include a circuit board, a light-emitting element, an inner photographing element, and an outer photographing element. The circuit board is connected to the bottom plate. The light-emitting element is electrically connected to the circuit board. The inner photographing element is electrically connected to the circuit board. The outer photographing element is electrically connected to the circuit board.

The invention relates to the technical field of medical monitoring equipment, in particular to an intelligent drainage monitoring system and method after a hepatotomy based on multi-modal sensing, and the system comprises a sensing data collection module, a signal processing module, a data fusion analysis module and an abnormity recognition early warning module. The sensing data acquisition module comprehensively acquires pressure, component and diffusion state data of drainage liquid by utilizing an optical fiber pressure sensor array, a micro spectral analysis device and a biological impedance sensor, the signal processing module converts sensing data into digital signals, and the data fusion analysis module performs fusion analysis on the drainage liquid based on the signals. According to the system, the content of bilirubin and hemoglobin in drainage liquid and the diffusion state of the bilirubin and hemoglobin in the abdominal cavity are recognized and comprehensively analyzed, the abnormity recognition and early warning module compares an analysis result with a preset normal index, the abnormal condition is determined, an early warning signal is generated, the intelligence and accuracy of drainage management are effectively improved, and the working efficiency is improved. Postoperative complications can be reduced, and the rehabilitation quality of a patient can be improved.

The application relates to the technical field of biological pharmacy, and discloses a method for preparing high-bionic bovine bezoar by using a 3D printing technology and application. The preparation raw material of the high-bionic bovine bezoar comprises the following components: fermented bovine bile, saturated calcium hydroxide, hydroxypropyl methyl cellulose, bilirubin, cholic acid, deoxycholic acid and taurine; wherein the fermented bovine bile is obtained by fermenting bovine bile by using escherichia coli. The high-bionic bovine bezoar prepared by using the preparation raw material to perform 3D printing can be comparable to natural bovine bezoar in terms of components, effects and appearance, the main pharmaceutical components can be adjusted according to actual requirements, the production cost of the bovine bezoar can be greatly reduced, and the demand of people for the bovine bezoar can be met.

The invention discloses a compound applied to a hemolytic agent and a composition thereof, which are characterized in that a compound which has weak reducibility and can be combined with hemachrome oxygenase to limit enzymatic activity is introduced into a formula of the hemolytic agent, so that the combination ratio of saponin and hemachrome oxygenase is reduced; according to the present invention, the dependence degree of the heme-biliverdin-bilirubin oxidation reduction system on the saponin is limited, the compatibility of the hemolytic agent formula on different batches of commercial saponin products is improved, and the weak reducibility of the compound avoids the oxidation problem of the saponin on the premise of no influence on the disulfide bond of the antibody, such that the heme-biliverdin-bilirubin oxidation reduction system can be easily obtained. Finally, the effects of reducing batch-to-batch clinical deviation of the hemolytic agent and improving the long-term stability of the hemolytic agent are achieved.

The invention discloses a protein / polysaccharide composite dialysis membrane based on in-situ loaded lanthanum carbonate and application of the protein / polysaccharide composite dialysis membrane, a lanthanum carbonate loaded protein / polysaccharide composite aggregate is used for modifying a porous filter membrane, and the dialysis membrane with a lanthanum carbonate loaded protein / polysaccharide self-assembled membrane as a compact skin layer and the porous filter membrane as a supporting layer is formed. By integrating a membrane separation mechanism of hemodialysis and an adsorption principle of blood perfusion, the skin layer of the dialysis membrane has molecular sieve separation and chemical adsorption functions, efficient removal of molecular uremic toxins (phosphorus, creatine liver, bilirubin, p-cresol sulfate and indol sulfate) with different sizes is synergistically realized, macromolecular proteins in blood are effectively intercepted by pore size screening, and the dialysis membrane has the advantages of simple structure, low cost and high efficiency. According to the present invention, by using the adsorption effect of the functional group on the surface of the membrane, the high removal rate on the protein-bound urotoxin is achieved, the high removal effect on phosphorus is particularly achieved, the blood compatibility is considered, the large-scale preparation is easily achieved, and the new idea is provided for the development of the high-performance blood purification material.

The invention discloses a human bilirubin content detection method and device, a storage medium and a server. The human bilirubin content detection method comprises the following steps: acquiring face video data; face blood filling degree caused by blood pulsation in face video data is identified to determine spectrums with different wavelengths, and a target dynamic spectrum is extracted from the spectrums; performing model training based on the target dynamic spectrum by using a partial least squares regression algorithm to obtain a bilirubin detection model; receiving a to-be-detected face video configured by a to-be-detected user, inputting the to-be-detected face video into the bilirubin detection model, and predicting to obtain the human bilirubin content of the to-be-detected user; the technical problem that the intelligent level is not high due to the fact that the corresponding spectrum cannot be extracted through analysis of the face video is solved.

This invention provides a process for extracting biliverdin hydrochloride through bio-fermentation and a method for synthesizing bilirubin. By studying the complex system of biliverdin obtained through microbial bacterial fermentation, a process for separating and purifying biliverdin was established, and the obtained biliverdin was further used to synthesize bilirubin. This process is simple to operate, uses common resins, employs solvents with low toxicity that are easily recovered and reused, utilizes low-energy membrane separation equipment for concentration, and uses conventional reaction reagents as reducing agents. The process has low operating costs, is environmentally friendly, and yields high-purity and stable-yield biliverdin and bilirubin products, demonstrating excellent prospects for industrial application.

The invention relates to the technical field of bilirubin extraction, in particular to a bilirubin extraction-based heating and cooling tank for biological pharmacy, which comprises a tank body, a stirring mechanism is arranged in the tank body, one end of the top of the tank body is communicated with an exhaust pipe, and a plurality of uniformly distributed exhaust holes are formed in the top end of the exhaust pipe. A shielding seat is fixedly mounted at the top of the exhaust pipe, the exhaust pipe is fixedly sleeved with a collecting box, a defoaming mechanism and a pushing mechanism are arranged in the exhaust pipe, and a defoaming agent spraying mechanism is arranged in the collecting box. The device has the beneficial effects that the defoaming mechanism is arranged in the exhaust pipe, when the foam amount exceeds the processing capacity of a defoaming paddle and is sprayed out from the exhaust pipe, the two defoaming plates in the defoaming mechanism pierce and eliminate the foam, and in the process of extracting bilirubin through pig bile in biological pharmacy, the defoaming effect is good. And the problem of bilirubin loss caused by the fact that foam sprayed out of the exhaust pipe carries part of bilirubin is avoided.

Disclosed herein are improved pluripotent stem cell-derived multi-zonal liver organoids, having two or more hepatocyte subpopulations, and methods of producing the same, by coculturing a first human liver organoid (HLO) with a bilirubin-treated second HLO, and contacting the co-cultured HLOs with bilirubin for a period of time sufficient for the co-cultured HLOs to self-assemble and fuse into interconnected dual organoids. The first HLO can be an ascorbateenriched HLO, such as a functional L-gulonolactone oxidase (GULO)-expressing HLO. In particular embodiments, the hepatocyte subpopulations can include zone 1 and zone 3 hepatocyte subpopulations, or zone 1, zone 2, and zone 3 hepatocyte subpopulations. Also disclosed are methods of studying or treating a liver-related disease or disorder using the described multi-zonal liver organoids.

The invention belongs to the technical field of biochemical pharmacy, and particularly relates to a compound bezoar composition, decoction piece type compound bezoar and a preparation method of the decoction piece type compound bezoar. The compound calculus bovis composition provided by the invention comprises 94-96% by mass of main agents and 8 kinds of calculus bovis intermediates, the mass content of the auxiliary agent is 4-6%, and the auxiliary agent is six commercially available finished product combined cholic acid. The bilirubin content of the bezoar intermediate used in the invention is increased by more than 30% and the yield is increased by more than 25% compared with the existing biochemical reaction process of oxgall. The DPPH free radical scavenging rate of the compound bezoar composition reaches 89.6% + / -2.1% and is increased by 25.7-36.9% compared with 58.3% + / -3.5% of a product prepared from ox bile, and through t inspection, p is smaller than 0.01 (n is equal to 5). Free cholic acid intervention is strictly prohibited, lithocholic acid addition is completely eradicated, and the composition has the advantages of being high in bilirubin content, high in oxidation resistance and high in biological activity and adapts to the physiological characteristics of the human body.

This invention discloses a single-herb bezoar preparation based on an ancient prescription; an enteric-coated bezoar soft capsule and its preparation method. The enteric-coated bezoar soft capsule consists of a bezoar dispersion and an enteric-coated soft capsule shell. A sand mill is used to prepare bezoar powder into micron-sized particles with a particle size ≤100μm. The micron-sized bezoar powder is fully dispersed in a dispersion medium, thereby improving the solubility of bezoar. The single-herb bezoar preparation can improve the problem of inconsistent bezoar content in compound bezoar preparations. The process of preparing the ≤100μm micron-sized bezoar dispersion uses non-metallic grinding equipment, avoiding the catalytic reaction of metal ions during the preparation of micron-sized powder. Low-temperature grinding is also used to avoid denaturation of the heat-sensitive active substances in bezoar, better preserving its biological activity. The enteric-coated formulation prevents the drug from being released in the stomach until it reaches the small intestine, avoiding the precipitation of bilirubin and other bile acids in the acidic environment of the stomach, which would otherwise lead to insoluble solids and poor solubility.

The invention discloses a platelet antibody detection kit and application thereof. Belongs to the technical field of detection kits. The kit comprises a microcolumn gel card, an enzyme-labeled secondary antibody, an enzyme-labeled secondary antibody diluent, a 20x washing solution, a developing solution, a fresh platelet treatment solution, a platelet buffer solution, a platelet preparation solution, a freeze-dried platelet reconstitution fluid, freeze-dried platelets and a negative control. The platelet antibody detection kit disclosed by the invention has the beneficial effects that the platelet antibody detection kit disclosed by the invention enables cross-matching of platelets to be possible; according to the invention, a micro-column gel immunoassay technology is combined with an enzyme immunolabeling technology, so that the limitation that only agglutination reaction can be carried out in a micro-column gel method is solved; according to the reaction card washing equipment disclosed by the invention, semi-automatic operation of micro-column gel method detection is realized; in the plasma, triglyceride is less than or equal to 5mg / mL, bilirubin is less than or equal to 20mg / dL, and hemoglobin is less than or equal to 5mg / mL, so that the result is not influenced; the kit has the advantages of good stability, long effective period, high sensitivity, strong specificity and simple operation.

A composition includes a compound of Formula 1, a solvate thereof, or a salt thereof. A method for treating an inflammatory disease includes administering the compound to a subject in need thereof. The compound of Formula 1 can protect cells and reduce inflammation by removing reactive oxygen species and suppressing inflammatory cytokines in a non-toxic manner.

The invention discloses a multi-layer composite artificial cochlea electrode coating material with multiple anti-inflammatory and electrode-neuron repairing functions and a preparation method of the multi-layer composite artificial cochlea electrode coating material. The preparation method specifically comprises the following steps: constructing a silver elementary substance coating on an artificial cochlea electrode platinum-iridium alloy contact base material by using a physical vapor deposition process; an electrode contact is obtained by combining a vacuum ultrashort pulse laser processing technology, and a methacrylated silk fibroin SilMA microsphere material loaded with bilirubin is prepared by a microfluidic technology; preparing gold-copper clustering enzyme by using a wet chemical reduction method; the preparation method comprises the following steps: preparing a porous methacrylated gelatin solution, composite neural stem cells, SilMA drug-loaded microspheres and gold-copper clustered enzyme; after in-situ curing and demolding are carried out on the surface of the artificial cochlea electrode by combining a mold pouring method, a multi-layer composite artificial cochlea electrode coating material with multiple anti-inflammatory and electrode-neuron repairing functions is obtained on the surface of the electrode, and the coating can provide a cell source for nerve deafness repairing and complete electrode-neuron repairing; and multiple anti-inflammatory functions are realized.

The application belongs to the field of biological detection, and particularly relates to a technology and a reagent for detecting NAG by a VRA-NAG substrate method. The linear range of the NAG detection reagent provided by the application can reach (0, 500] U / L; within the range, when the anti-acid is less than or equal to 340 micromoles / L, urea is less than or equal to 42.9 millimoles / L, uric acid is less than or equal to 1.4 millimoles / L, albumin is less than or equal to 100 milligrams / dL, bilirubin is less than or equal to 342 micromoles / L, lactic acid is less than or equal to 6.6 millimoles / L, glucose is less than or equal to 55 millimoles / L, triglyceride is less than or equal to 37 millimoles / L, and oxalic acid is less than or equal to 81 micromoles / L, these components have no obvious interference on the test. Moreover, the relative standard deviation caused by the accelerated aging of the detection reagent for 10 days is not more than ±10%. Compared with the prior art, the kit provided by the application has high sensitivity, wide linear range, strong specificity and good stability, and is conducive to early detection and early treatment of kidney diseases in clinical practice.

The invention discloses a method for culturing calculus bovis by utilizing flora, which is characterized in that cattle gall bladders obtained by slaughtering are used as reaction containers, so that the animal welfare problem caused by living body surgery is completely avoided. A plurality of key steps of bilirubin generation, cholesterol conversion, matrix formation and the like are synergistically completed by adopting functional complementary synthetic flora, and the components of the generated product are closer to a complex system of natural calculus bovis. The breeding is carried out in a closed bioreactor with controllable parameters, uncontrollable factors such as individual cattle difference and feeding environment are eliminated, and the product quality is highly stable and uniform. Automatic monitoring and feedback control are achieved in the whole cultivation process, and technological parameters are accurate and adjustable. The used strains are all non-pathogenic or food-grade safe strains, and the whole process is sterile, free of exogenous pathogen pollution and antibiotic residue risks, and high in biological safety.

The invention belongs to the field of medicine, and discloses application of bilirubin in preparation of a medicine for treating central nervous system autoimmune diseases, the bilirubin can relieve the clinical symptom severity of the central nervous system autoimmune diseases, relieve the demyelination injury severity of the central nervous system autoimmune diseases, and improve the curative effect of the central nervous system autoimmune diseases. The composition can be used for relieving microglial cell activation in the central nervous system autoimmune diseases, relieving inflammatory cell infiltration in the central nervous system autoimmune diseases and relieving neuroinflammatory response in the central nervous system autoimmune diseases. Good clinical application values are realized.

Disclosed herein are modified cyclodextrin compounds (e.g., compounds of Formula I, I-a, Lal, Lb, Lbl, Lc, or Lcl) and methods of their use (e.g. methods of sequestering bilirubin by administering said compounds).

The invention discloses a 3-ethyl-4-methyl-3-pyrrolin-2-one false template molecularly imprinted adsorption material for removing bilirubin as well as a preparation method and application of the 3-ethyl-4-methyl-3-pyrrolin-2-one false template molecularly imprinted adsorption material. 3-ethyl-4-methyl-3-pyrroline-2-ketone with a molecular structure similar to that of bilirubin is used as a false template molecule, 3-aminopropyltriethoxysilane is used as a functional monomer, tetraethoxysilane is used as a cross-linking agent, absolute ethyl alcohol is used as a solvent, and ultrapure water is used for catalytic hydrolysis to obtain the bilirubin fluorescent probe. A molecularly imprinted polymer adsorbent material is prepared and synthesized by using a sol-gel method; after the false template molecules in the adsorbent material are eluted, imprinted holes left in the material can specifically adsorb bilirubin molecules similar to the false template molecules in structure, so that the purpose of highly selectively adsorbing and removing the bilirubin molecules is achieved. The preparation method disclosed by the invention is simple and convenient to operate, low in cost and high in repeatability, and the 3-ethyl-4-methyl-3-pyrroline-2-one false template molecularly imprinted adsorption material has relatively high adsorption capacity, strong specificity and high biological safety.

The application belongs to the technical field of medical equipment, and provides a blood treatment system including a blood treatment assembly, an optical detection assembly and a control module. The blood treatment assembly uses a treatment liquid to treat blood of a target object to obtain waste liquid and treated blood, and the treated blood is transfused back to the target object. The optical detection assembly generates irradiation light of at least three wavelengths, wherein the irradiation light of the first wavelength is used for detecting bilirubin or free hemoglobin, the irradiation light of the second wavelength is used for detecting intracellular hemoglobin, and the irradiation light of the third wavelength is used for detecting the waste liquid. The optical detection assembly collects light information of emergent light of the at least three wavelengths. The control module obtains light change information corresponding to the at least three wavelengths according to the light information of the emergent light of the at least three wavelengths and the light information of the irradiation light of the at least three wavelengths. Whether the light change information corresponding to the at least three wavelengths satisfies a preset alarm condition is judged to determine whether to perform a hemolysis alarm or a blood leakage alarm, so that detection is distinguished.

A method of treating a disease or disorder characterized by aberrant or dysregulated nitrosylation in a subject, the method comprising administering to the subject a therapeutically effective amount of an agent that modulates SNO-CoA-associated Nitrosyltransferase (SCAN) mediated S-nitrosylation. In some embodiments, it includes an agent that modulates SNO-CoA- associated Nitrosyltransferase (SCAN)Zbiliverdin IXB reductase B (SCAN7BLVRB) mediated S-nitrosylation and its use in methods of treating diseases and disorders characterized by aberrant or dysregulated nitrosylation in a subject in need thereof.